Status:

COMPLETED

Mylan Insulin Aspart Study

Lead Sponsor:

Mylan Inc.

Collaborating Sponsors:

Mylan GmbH

Conditions:

Diabetes Mellitus, Type 1

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

The aim of this phase III trial is to demonstrate the equivalence in the safety and efficacy profile between MYL-1601D and NovoLog® in patients with T1DM.

Detailed Description

This is a multicenter, open-label, randomized, parallel-group phase 3 study in subjects with T1DM comparing the safety and efficacy of MYL-1601D with NovoLog®. After up to 3-week screening period, al...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Written and signed informed consent.
  • Clinical diagnosis of type 1 diabetes mellitus for at least 6 months prior to screening.
  • Subject is able and willing to comply with the requirements of the study protocol.
  • Exclusion Criteria
  • History or presence of a medical condition or disease that in the Investigator's opinion would place the subject at an unacceptable risk from study participation.
  • History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the study, OR history of significant allergic drug reactions.
  • Any clinically significant abnormality in electrocardiogram or safety laboratory tests.
  • Any elective surgery requiring hospitalization planned during the study period.
  • History of a significant medical condition, such as unstable angina, myocardial infarction, stroke or transient ischemic attack in the 6 months before screening.
  • Subjects with major depressive illness in the last 3 years.
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Exclusion

    Key Trial Info

    Start Date :

    November 7 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 17 2020

    Estimated Enrollment :

    478 Patients enrolled

    Trial Details

    Trial ID

    NCT03760068

    Start Date

    November 7 2018

    End Date

    January 17 2020

    Last Update

    February 25 2022

    Active Locations (158)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 40 (158 locations)

    1

    Endocrinology Associates Montgomery

    Montgomery, Alabama, United States, 36106

    2

    Phoenician Centers for Research

    Phoenix, Arizona, United States, 85012

    3

    Precision Trials

    Phoenix, Arizona, United States, 85032

    4

    Medical Investigations Inc.

    Little Rock, Arkansas, United States, 72211